

# FcRn Blockers (Rystiggo®, Vyvgart®, & Vyvgart Hytrulo®)

**Policy Number:** 2025D0111K  
**Effective Date:** October 1, 2025

[➔ Instructions for Use](#)

Table of Contents	Page
<a href="#">Coverage Rationale</a>	1
<a href="#">Applicable Codes</a>	4
<a href="#">Background</a>	5
<a href="#">Benefit Considerations</a>	5
<a href="#">Clinical Evidence</a>	5
<a href="#">U.S. Food and Drug Administration</a>	9
<a href="#">Centers for Medicare and Medicaid Services</a>	9
<a href="#">References</a>	9
<a href="#">Policy History/Revision Information</a>	10
<a href="#">Instructions for Use</a>	10

## Related Commercial Policy

- [Provider Administered Drugs – Site of Care](#)

## Community Plan Policy

- [FcRn Blockers \(Rystiggo®, Vyvgart®, & Vyvgart Hytrulo®\)](#)

## Coverage Rationale

[➔ See Benefit Considerations](#)

Imaavy™ (nipocalimab-aahu) has been added to the Review at Launch program. Some members may not be eligible for coverage of this medication at this time. Refer to the Medical Benefit Drug Policy titled [Review at Launch for New to Market Medications](#) for additional details.

This policy refers to the following drug products for administration by a healthcare professional:

- Rystiggo (rozanolixizumab-noli) for intravenous (IV) route
- Vyvgart (efgartigimod alfa-fcab) for intravenous (IV) route
- Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) vial for subcutaneous (SC) route

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for self-administered subcutaneous injection is obtained under the pharmacy benefit, unless otherwise specified in the member's benefit plan documents. Exception: For members enrolled in UnitedHealthcare of California plans with a delegated provider group conducting the prior authorization review, the self-administered Vyvgart Hytrulo may be obtained under the medical benefit.

**Rystiggo is proven for the treatment of generalized myasthenia gravis in patients who are anti-acetylcholine receptor (AChR) antibody positive or antimuscle-specific tyrosine kinase (MuSK) antibody positive. Rystiggo is medically necessary for the treatment of generalized myasthenia gravis in patients who are anti-AChR antibody positive or anti-MuSK antibody positive when all of the following criteria are met:**

- **Initial Therapy**
  - Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming **all** of the following:
    - Patient has not failed a previous course of Rystiggo therapy; **and**
    - Diagnosis of generalized myasthenia gravis (gMG); **and**
    - **One** of the following:
      - Positive serologic test for anti-AChR antibodies; **or**
      - Positive serologic test for anti-MuSK antibodies
    - and**
    - Patient has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy; **and**

- Patient has a Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total score  $\geq 5$  at initiation of therapy

**and**

- **One** of the following: (for Medicare reviews, refer to the [CMS](#) section\*)
  - If anti-acetylcholine receptor (AChR) antibody positive, one of the following:
    - History of failure of at least **two** immunosuppressive agents over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.); **or**
    - Patient has a history of failure of at least one immunosuppressive therapy and has required four or more courses of plasmapheresis/plasma exchanges and/or immune globulin over the course of at least 12 months without symptom control
  - If anti-muscle-specific tyrosine kinase (MuSK) antibody positive:
    - History of failure of at least one immunosuppressive agent over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.)

**and**

- Patient is **not** receiving Rystiggo in combination with a complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)]; **and**
- Patient is **not** receiving Rystiggo in combination with another FcRn blocker [e.g., Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]; **and**
- Patient is **not** receiving Rystiggo in combination with an immune globulin; **and**
- Rystiggo is dosed according to the US FDA labeled dosing for gMG; **and**
- Prescribed by, or in consultation with, a neurologist; **and**
- Initial authorization will be for no more than 12 months

- **Continuation of Therapy**

- Patient has previously been treated with Rystiggo; **and**
- Submission of medical records (e.g., chart notes, laboratory tests) demonstrating **all** of the following:
  - Improvement and/or maintenance of at least a 2 point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline; **and**
  - Reduction in signs and symptoms of myasthenia gravis; **and**
  - Maintenance, reduction, or discontinuation of dose(s) of baseline immunosuppressive therapy (IST) prior to starting Rystiggo (**Note:** Add on, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Rystiggo therapy will be considered as treatment failure.)

**and**

- Patient is **not** receiving Rystiggo in combination with a complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)]; **and**
- Patient is **not** receiving Rystiggo in combination with another FcRn blocker [e.g., Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]; **and**
- Patient is **not** receiving Rystiggo in combination with an immune globulin; **and**
- Rystiggo is dosed according to the US FDA labeled dosing for gMG; **and**
- Prescribed by, or in consultation with, a neurologist; **and**
- Reauthorization will be for no more than 12 months

**Vyvgart and Vyvgart Hytrulo are proven for the treatment of generalized myasthenia gravis in patients who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart and Vyvgart Hytrulo are medically necessary for the treatment of generalized myasthenia gravis in patients who are anti-AChR antibody positive when all of the following criteria are met:**

- **Initial Therapy**

- Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming **all** of the following:
  - Patient has not failed a previous course of Vyvgart therapy; **and**
  - Patient has not failed a previous course of Vyvgart Hytrulo therapy; **and**
  - Diagnosis of generalized myasthenia gravis (gMG); **and**
  - Positive serologic test for anti-AChR antibodies; **and**
  - Patient has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy; **and**
  - Patient has a Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total score  $\geq 5$  at initiation of therapy

**and**

- **One** of the following: (for Medicare reviews, refer to the [CMS](#) section\*)
  - History of failure of at least **two** immunosuppressive agents over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.); **or**

- Patient has a history of failure of at least one immunosuppressive therapy and has required four or more courses of plasmapheresis/plasma exchanges and/or immune globulin over the course of at least 12 months without symptom control

**and**

- Patient will be given Vyvgart or Vyvgart Hytrulo no sooner than 50 days after each treatment cycle; **and**
- Patient is **not** receiving Vyvgart or Vyvgart Hytrulo in combination with a complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)]; **and**
- Patient is **not** receiving Vyvgart or Vyvgart Hytrulo in combination with another FcRn blocker [e.g., Rystiggo (rozanolixizumab-noli)]; **and**
- Patient is **not** receiving Vyvgart or Vyvgart Hytrulo in combination with an immune globulin; **and**
- Vyvgart or Vyvgart Hytrulo is dosed according to the US FDA labeled dosing for gMG; **and**
- Prescribed by, or in consultation with, a neurologist; **and**
- Initial authorization will be for no more than 12 months

- **Continuation of Therapy**

- Patient has previously been treated with Vyvgart or Vyvgart Hytrulo; **and**
- Submission of medical records (e.g., chart notes, laboratory tests) demonstrating **all** of the following:
  - Improvement and/or maintenance of at least a 2 point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline;<sup>6</sup> **and**
  - Reduction in signs and symptoms of myasthenia gravis; **and**
  - Maintenance, reduction, or discontinuation of dose(s) of baseline immunosuppressive therapy (IST) prior to starting Vyvgart or Vyvgart Hytrulo (**Note:** Add on, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Vyvgart or Vyvgart Hytrulo therapy will be considered as treatment failure.)

**and**

- Patient is **not** receiving Vyvgart or Vyvgart Hytrulo in combination with a complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)]; **and**
- Patient is **not** receiving Vyvgart or Vyvgart Hytrulo in combination with another FcRn blocker [e.g., Rystiggo (rozanolixizumab-noli)]; **and**
- Patient is **not** receiving Vyvgart or Vyvgart Hytrulo in combination with an immune globulin; **and**
- Vyvgart or Vyvgart Hytrulo is dosed according to the US FDA labeled dosing for gMG; **and**
- Prescribed by, or in consultation with, a neurologist; **and**
- Reauthorization will be for no more than 12 months

**Vyvgart Hytrulo is proven for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).**

**Vyvgart Hytrulo is medically necessary for the treatment of CIDP when all of the following criteria are met:**<sup>12</sup>

- **Initial Therapy**

- Patient has not failed a previous course of Vyvgart Hytrulo therapy; **and**
- Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP); **and**
- Diagnosis of CIDP is categorized as **one** of the following:
  - Typical CIDP; **or**
  - **One** of the following CIDP variants:
    - Distal CIDP
    - Multifocal CIDP
    - Focal CIDP
    - Motor CIDP
    - Sensory CIDP

**and**

- **One** of the following:
  - Electrodiagnostic testing has confirmed at least two motor nerve abnormalities; **or**
  - **All** of the following:
    - Electrodiagnostic testing allows only for a diagnosis of possible CIDP having only one motor nerve abnormality; **and**
    - **Two** of the following, consistent with [EFNS/PNS guidelines](#), support a diagnosis of possible CIDP
      - Objective response to treatment with immunomodulatory agents (e.g., corticosteroids, immune globulin, plasma exchange)
      - Imaging with ultrasound or MRI
      - Cerebrospinal fluid (CSF) analysis
      - Nerve Biopsy

**and**

- Immunological testing [e.g., nodal and paranodal antibodies, serum protein electrophoresis and immunofixation, spot urine immunofixation for light chains, measurement of serum free light chains (SFLC), anti-MAG antibody] has excluded other possible relevant neuropathies (e.g., anti-MAG IgM neuropathy, multiple myeloma, AL-amyloidosis, POEMS syndrome)

**and**

- Trial and failure (after a trial of at least two months), contraindication, or intolerance to corticosteroids (for Medicare reviews, refer to the [CMS](#) section\*); **and**
- Trial and failure (after a trial of at least three months), contraindication, or intolerance to Immune globulin (i.e., intravenous immunoglobulin or subcutaneous immunoglobulin) based on **both** of the following (for Medicare reviews, refer to the [CMS](#) section\*):
  - Dose has been adjusted or escalated to the maximally allowable and/or tolerated dose; **and**
  - **Both** of the following:
    - Failure to obtain an objective response to treatment in a disability assessment defined by **one** of the following:
      - Inflammatory Rasch-built Overall Disability Scale (I-RODS): increase  $\geq 4$  centile points in a 48-point scale; **or**
      - Inflammatory Neuropathy Cause and Treatment Disability Scale (INCAT): decrease  $\geq 1$  point
    - and**
    - Failure to obtain an objective response to treatment in an impairment assessment defined by **one** the following:
      - Grip strength using handheld dynamometry in Martin Vigorimeter: increase  $\geq 8$  kilopascals (or  $\geq 1.2$  pounds/inch<sup>2</sup>) or Jamar hand grip dynamometer: increase  $\geq 10\%$ ; **or**
      - Medical Research Council (MRC) sum score (0-60): increase  $\geq 2$  to 4 points; **or**
      - Modified INCAT Sensory Sum scale (mISS): decrease  $\geq 2$  points

**and**

- Patient is **not** receiving Vyvgart Hytrulo in combination with an immune globulin; **and**
- Vyvgart Hytrulo is dosed according to the US FDA labeled dosing for CIDP; **and**
- Prescribed by, or in consultation with, a neurologist; **and**
- Initial authorization will be for no more than 12 months
- **Continuation of Therapy**
  - Patient has previously been treated with Vyvgart Hytrulo; **and**
  - Documentation of positive clinical response to therapy as measured by an objective scale [e.g., Rankin, Modified Rankin, Medical Research Council (MRC) scale]; **and**
  - Patient is **not** receiving Vyvgart Hytrulo in combination with an immune globulin; **and**
  - Vyvgart Hytrulo is dosed according to the US FDA labeled dosing for CIDP; **and**
  - Prescribed by, or in consultation with, a neurologist; **and**
  - Reauthorization will be for no more than 12 months

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPSC Code	Description
C9305	Injection, nipocalimab-aahu, 3 mg
J9332	Injection, efgartigimod alfa-fcab, 2 mg
J9333	Injection, rozanolixizumab-noli, 1 mg
J9334	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc

Diagnosis Code	Description
G61.81	Chronic inflammatory demyelinating polyneuritis
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation

## Background

Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG. The pharmacological effect of efgartigimod alfa-fcab was assessed by measuring the decrease in serum IgG levels and AChR autoantibody levels. In patients testing positive for AChR antibodies and who were treated with efgartigimod alfa-fcab, there was a reduction in total IgG levels relative to baseline. Decrease in AChR autoantibody levels followed a similar pattern.

Efgartigimod alfa and hyaluronidase-qvfc is a coformulation of efgartigimod alfa and hyaluronidase. Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG. Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. This effect is transient and permeability of the subcutaneous tissue is restored within 24 to 48 hours.

Rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.

## Benefit Considerations

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy.

**Additional Information:** Clinical coverage in this policy addresses the drug only. It does not address coverage for drug administration in a hospital outpatient department. Refer to the member specific benefit plan document and the Medical Benefit Drug Policy titled [Provider Administered Drugs – Site of Care](#) for more information. The member specific benefit plan document determines coverage.

## Clinical Evidence

### Generalized Myasthenia Gravis

Efgartigimod alfa-fcab is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

The efficacy of efgartigimod alfa-fcab for the treatment of generalized myasthenia gravis (gMG) in adults who are AChR antibody positive was established in a 26-week, multicenter, randomized, double-blind, placebo-controlled trial (Study 1; NCT03669588).

Study 1 enrolled patients who met the following criteria at screening:

- Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV
- MG-Activities of Daily Living (MG-ADL) total score of  $\geq 5$
- On stable dose of MG therapy prior to screening, that included acetylcholinesterase (AChE) inhibitors, steroids, or non-steroidal immunosuppressive therapies (NSISTs), either in combination or alone
- IgG levels of at least 6 g/L

A total of 167 patients were enrolled in Study 1 and were randomized to receive either efgartigimod alfa-fcab 10mg/kg (1200 mg for those weighing 120 kg or more) (n = 84) or placebo (n = 83). Baseline characteristics were similar between treatment groups. Patients had a median age of 46 years at screening (range: 19 to 81 years) and a median time since diagnosis of 9 years. Seventy-one percent were female, and 84% were White. Median MG-ADL total score was 9, and median Quantitative Myasthenia Gravis (QMG) total score was 16. The majority of patients (n = 65 for efgartigimod alfa-fcab; n = 64 for placebo) were positive for AChR antibodies.

At baseline, over 80% of patients in each group received AChE inhibitors, over 70% in each treatment group received steroids, and approximately 60% in each treatment group received NSISTs, at stable doses.

Patients were treated with efgartigimod alfa-fcab at the recommended dosage regimen.



The efficacy of efgartigimod alfa-fcab was measured using the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) which assesses the impact of gMG on daily functions of 8 signs or symptoms that are typically affected in gMG. Each item is assessed on a 4-point scale where a score of 0 represents normal function and a score of 3 represents loss of ability to perform that function. A total score ranges from 0 to 24, with the higher scores indicating more impairment. In this study, an MGADL responder was defined as a patient with a 2-point or greater reduction in the total MG-ADL score compared to the treatment cycle baseline for at least 4 consecutive weeks, with the first reduction occurring no later than 1 week after the last infusion of the cycle. Studies have used different thresholds of change in MG-ADL score to indicate clinically meaningful change.<sup>6,7</sup> In a validation study that aimed to determine the change in MG-ADL value that would best predict improvement in MG clinical status, results from sensitivity and specificity analyses indicated that a 1-point change in MG-ADL was highly sensitive (96%) but did not have good specificity (71%), and a 3-point change had good specificity (90%) but was not very sensitive (62%). A 2-point change provided a balance between sensitivity (77%) and specificity (82%).

The primary efficacy endpoint was the comparison of the percentage of MG-ADL responders during the first treatment cycle between treatment groups in the AChR-Ab positive population. A statistically significant difference favoring efgartigimod alfa-fcab was observed in the MG-ADL responder rate during the first treatment cycle [67.7% in the efgartigimod alfa-fcab treated group vs 29.7% in the placebo-treated group ( $p < 0.0001$ )].

The efficacy of efgartigimod alfa-fcab was also measured using the Quantitative Myasthenia Gravis (QMG) total score which is a 13-item categorical grading system that assesses muscle weakness. Each item is assessed on a 4-point scale where a score of 0 represents no weakness and a score of 3 represents severe weakness. A total possible score ranges from 0 to 39, where higher scores indicate more severe impairment. In this study, a QMG responder was defined as a patient who had a 3-point or greater reduction in the total QMG score compared to the treatment cycle baseline for at least 4 consecutive weeks, with the first reduction occurring no later than 1 week after last infusion of the cycle.

The secondary endpoint was the comparison of the percentage of QMG responders during the first treatment cycle between both treatment groups in the AChR-Ab positive patients. A statistically significant difference favoring VYVGART was observed in the QMG responder rate during the first treatment cycle [63.1% in the efgartigimod alfa-fcab -treated group vs 14.1% in the placebo-treated group ( $p < 0.0001$ )].

Efgartigimod alfa and hyaluronidase-qvfc is indicated for the treatment of gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Study 1 (described above) which established the effectiveness of efgartigimod alfa-fcab for the treatment of gMG in adults who are AChR antibody positive was conducted with efgartigimod alfa-fcab intravenous formulation. In Study 2, efgartigimod alfa and hyaluronidase-qvfc demonstrated a comparable pharmacodynamic effect on AChR antibody reduction as compared to the efgartigimod alfa-fcab intravenous formulation, which established the efficacy of efgartigimod alfa and hyaluronidase-qvfc. In Study 2, the pharmacological effect of efgartigimod alfa and hyaluronidase-qvfc administered subcutaneously (SC) at 1,008 mg / 11,200 Units was compared to efgartigimod alfa-fcab administered intravenously at 10 mg/kg (EFG IV) in gMG patients. The maximum mean reduction in AChR-Ab level was observed at week 4, with a mean reduction of 62.2% and 59.7% in the efgartigimod alfa and hyaluronidase-qvfc SC and efgartigimod alfa-fcab IV arm, respectively. The decrease in total IgG levels followed a similar pattern. The 90% confidence intervals for the geometric mean ratios of AChR-Ab reduction at day 29 and AUEC<sub>0-4w</sub> (area under the effect-time curve from time 0 to 4 weeks post dose) were within the range of 80% to 125%, indicating no clinically significant difference between the two formulations.

The efficacy of rozanolixizumab-noli for the treatment of gMG in adults who are anti-AChR antibody positive or anti-MuSK antibody positive was established in a multicenter, randomized, double-blind, placebo-controlled study (Study 1; NCT03971422). The study included a 4-week screening period and a 6-week treatment period followed by 8 weeks of observation. During the treatment period, rozanolixizumab-noli or placebo were administered subcutaneously once a week for six weeks.

Study 1 enrolled patients who met the following criteria:

- Presence of autoantibodies against AChR or MuSK
- Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IVa
- Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score of at least 3 (with at least 3 points from non-ocular symptoms)
- On stable dose of MG therapy prior to screening that included acetylcholinesterase (AChE) inhibitors, steroids, or non-steroidal immunosuppressive therapies (NSISTs), either in combination or alone
- Serum IgG levels of at least 5.5 g/L

In Study 1, a total of 200 patients were randomized 1:1:1 to receive weight-tiered doses of rozanolixizumab-noli ( $n = 133$ ), equivalent to  $7 \text{ mg/kg}$  ( $n = 66$ ) or  $\approx 10 \text{ mg/kg}$  ( $n = 67$ ), or placebo ( $n = 67$ ). Baseline characteristics were similar between

treatment groups. Patients had a median age of 52 years at baseline (range: 18 to 89 years) and a median time since diagnosis of 6 years. Sixty-one percent of patients were female, 68% were White, 11% were Asian, 3% were Black or African American, 1% were American Indian or Alaska Native, and 7% were of Hispanic or Latino ethnicity. Median MG-ADL total score was 8, and the median Quantitative Myasthenia Gravis (QMG) total score was 15. The majority of patients, 89.5% (n = 179) were positive for AChR antibodies and 10.5% (n = 21) were positive for MuSK antibodies. At baseline in each group, over 83% of patients received AChE inhibitors, over 56% of patients received steroids, and approximately 50% received NSiSTs, at stable doses. Patients were treated with RYSTIGGO via subcutaneous infusion once per week for a period of 6 weeks, followed by an observation period of up to 8 weeks. The efficacy of rozanolixizumab-noli was measured using the MG-ADL scale. The primary efficacy endpoint was the comparison of the change from baseline between treatment groups in the MG-ADL total score at day 43. A statistically significant difference favoring rozanolixizumab-noli was observed in the MG-ADL total score change from baseline [-3.4 points in rozanolixizumab-noli -treated group at either dose vs -0.8 points in the placebo-treated group (p < 0.001)]. Reductions from baseline to day 43 in MG-ADL scores were observed in patients with AChR autoantibodypositive generalized myasthenia gravis [rozanolixizumab 7 mg/kg least-squares mean -3.03 (SE 0.89); rozanolixizumab 10 mg/kg -3.36 (0.87); placebo -1.10 (0.87); least-squares mean difference from placebo -1.94 (97.5% CI -3.06 to -0.81) and -2.26 (-3.39 to -1.13) in the rozanolixizumab 7 mg/kg and 10 mg/kg groups, respectively]. For patients with MuSK autoantibodypositive gMG, least-squares mean reductions were -7.28 (SE 1.94) in the rozanolixizumab 7 mg/kg group, -4.16 (1.78) in the rozanolixizumab 10 mg/kg group, and 2.28 (1.95) in the placebo group [least-squares mean difference from placebo for rozanolixizumab 7 mg/kg -9.56 (97.5% CI -15.25 to -3.87); -6.45 (-11.03 to -1.86) for the rozanolixizumab 10 mg/kg group].

## Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The efficacy of efgartigimod alfa and hyaluronidase-qvfc for CIDP was based on a two-stage study that included an open-label period to identify efgartigimod alfa and hyaluronidase-qvfc responders (stage A), who then entered a randomized, double-blind, placebo-controlled, withdrawal period (stage B). In stage B, a total of 221 patients were randomized to receive efgartigimod alfa and hyaluronidase-qvfc or placebo. The study enrolled male and female patients age 18 years and older, who at the time of screening, had a documented diagnosis of definite or probable CIDP using the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS; 2010) criteria for progressing or relapsing forms. The primary endpoint was the time to clinical deterioration defined as a 1-point increase in adjusted Inflammatory Neuropathy Cause and Treatment (aINCAT) at two consecutive visits or a > 1-point increase in aINCAT at one visit. Patients who received efgartigimod alfa and hyaluronidase-qvfc experienced a longer time to clinical deterioration compared to patients who received placebo (hazard ratio 0.394, 95% CI: 0.253, 0.614; p < 0.0001).

## Professional Societies

### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The European Academy of Neurology and Peripheral Nerve Society published in 2021 a second revision of a guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).<sup>12</sup> The task force refined the clinical criteria for defining CIDP into “typical CIDP” and “CIDP variants”. The task force also reduced the levels of electrodiagnostic certainty, as used in the 2010 EFNS/PNS guideline from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because of empirical evidence showing that the sensitivity and specificity of electrodiagnostic criteria for probable and definite CIDP do not significantly differ. In regard to the diagnosis of definite or probable CIDP, the task force concluded:

- **Clinical diagnostic criteria:**
  - Typical CIDP
    - All the following:
      - Progressive or relapsing, symmetric, proximal, and distal muscle weakness of upper and lower limbs, and sensory involvement of at least two limbs
      - Developing over at least 8 weeks
      - Absent or reduced tendon reflexes in all limbs
  - CIDP variants
    - One of the following, but otherwise as in typical CIDP (tendon reflexes may be normal in unaffected limbs):
      - Distal CIDP: distal sensory loss and muscle weakness predominantly in lower limbs
      - Multifocal CIDP: sensory loss and muscle weakness in a multifocal pattern, usually asymmetric, upper limb predominant, in more than one limb
      - Focal CIDP: sensory loss and muscle weakness in only one limb
      - Motor CIDP: motor symptoms and signs without sensory involvement
      - Sensory CIDP: sensory symptoms and signs without motor involvement
- **Electrodiagnostic criteria:**
  1. Strongly supportive of demyelination: At least one of the following:

- a. Motor distal latency prolongation  $\geq 50\%$  above ULN in two nerves (excluding median neuropathy at the wrist from carpal tunnel syndrome); or
  - b. Reduction of motor conduction velocity  $\geq 30\%$  below LLN in two nerves; or
  - c. Prolongation of F-wave latency  $\geq 20\%$  above ULN in two nerves ( $\geq 50\%$  if amplitude of distal negative peak CMAP  $< 80\%$  of LLN); or
  - d. Absence of F-waves in two nerves (if these nerves have distal negative peak CMAP amplitudes  $\geq 20\%$  of LLN) +  $\geq 1$  other demyelinating parameter\* in  $\geq 1$  other nerve; or
  - e. Motor conduction block:  $\geq 30\%$  reduction of the proximal relative to distal negative peak CMAP amplitude, excluding the tibial nerve, and distal negative peak CMAP amplitude  $\geq 20\%$  of LLN in two nerves; or in one nerve +  $\geq 1$  other demyelinating parameter\* except absence of F-waves in  $\geq 1$  other nerve; or
  - f. Abnormal temporal dispersion:  $> 30\%$  duration increase between the proximal and distal negative peak CMAP (at least  $100\%$  in the tibial nerve) in  $\geq 2$  nerves; or
  - g. Distal CMAP duration (interval between onset of the first negative peak and return to baseline of the last negative peak) prolongation in  $\geq 1$  nerve<sup>13</sup> +  $\geq 1$  other demyelinating parameter\* in  $\geq 1$  other nerve
    - (LFF 2 Hz) median  $> 8.4$  ms, ulnar  $> 9.6$  ms, peroneal  $> 8.8$  ms, tibial  $> 9.2$  ms
    - (LFF 5 Hz) median  $> 8.0$  ms, ulnar  $> 8.6$  ms, peroneal  $> 8.5$  ms, tibial  $> 8.3$  ms
    - (LFF 10 Hz) median  $> 7.8$  ms, ulnar  $> 8.5$  ms, peroneal  $> 8.3$  ms, tibial  $> 8.2$  ms
    - (LFF 20 Hz) median  $> 7.4$  ms, ulnar  $> 7.8$  ms, peroneal  $> 8.1$  ms, tibial  $> 8.0$  ms
2. Weakly supportive of demyelination: As in (1) but in only one nerve

\*Any nerve meeting any of the criteria (a-g)

In 2010, the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS 2010) published clinical guidelines for the management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).<sup>11</sup> In regard to the diagnosis of CIDP, the task force concluded:

- **Clinical diagnostic criteria:**

- Inclusion criteria:
  - **Typical CIDP**
    - Chronically progressive, stepwise, or recurrent symmetric proximal and distal weakness and sensory dysfunction of all extremities, developing over at least 2 months; cranial nerves may be affected; and
    - Absent or reduced tendon reflexes in all extremities
  - **Atypical CIDP** (still considered CIDP but with different features)  
One of the following, but otherwise as in Typical CIDP (tendon reflexes may be normal in unaffected limbs):
    - Predominantly distal (distal acquired demyelinating symmetric), DADS; or
    - Asymmetric [multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), Lewis–Sumner syndrome]; or
    - Focal (e.g., involvement of the brachial or lumbosacral plexus or of one or more peripheral nerves in one upper or lower limb); or
    - Pure motor; or
    - Pure sensory (including chronic immune sensory polyradiculopathy affecting the central process of the primary sensory neuron)

- **Electrodiagnostic criteria:**

- Definite: at least one of the following:
  - Motor distal latency prolongation  $\geq 50\%$  above ULN in two nerves (excluding median neuropathy at the wrist from carpal tunnel syndrome); or
  - Reduction of motor conduction velocity  $\geq 30\%$  below LLN in two nerves; or
  - Prolongation of F-wave latency  $\geq 20\%$  above ULN in two nerves ( $\geq 50\%$  if amplitude of distal negative peak CMAP  $< 80\%$  of LLN values); or
  - Absence of F-waves in two nerves if these nerves have distal negative peak CMAP amplitudes  $\geq 20\%$  of LLN +  $\geq 1$  other demyelinating parameter in  $\geq 1$  other nerve; or
  - Partial motor conduction block:  $\geq 50\%$  amplitude reduction of the proximal negative peak CMAP relative to distal, if distal negative peak CMAP  $\geq 20\%$  of LLN, in two nerves, or in one nerve +  $\geq 1$  other demyelinating parameter in  $\geq 1$  other nerve; or
  - Abnormal temporal dispersion ( $> 30\%$  duration increase between the proximal and distal negative peak CMAP) in  $\geq 2$  nerves; or
  - Distal CMAP duration (interval between onset of the first negative peak and return to baseline of the last negative peak) increase in  $\geq 1$  nerve (median  $\geq 6.6$  ms, ulnar  $\geq 6.7$  ms, peroneal  $\geq 7.6$  ms, tibial  $\geq 8.8$  ms) +  $\geq 1$  other demyelinating parameter in  $\geq 1$  other nerve



- Probable:  $\geq 30\%$  amplitude reduction of the proximal negative peak CMAP relative to distal, excluding the posterior tibial nerve, if distal negative peak CMAP  $\geq 20\%$  of LLN, in two nerves, or in one nerve +  $\geq 1$  other demyelinating parameter in  $\geq 1$  other nerve

## U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Vyvgart is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Vyvgart Hytrulo is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart Hytrulo is also indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Rystiggo is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti muscle-specific tyrosine kinase (MuSK) antibody positive.

## Centers for Medicare and Medicaid Services (CMS)

Medicare does not have a National Coverage Determination (NCD) for Vyvgart® (efgartigimod alfa-fcab), Vyvgart® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) and Rystiggo® (rozanolixizumab-noli). Local Coverage Determinations/Articles (LCDs/LCAs) do not exist.

In general, Medicare covers outpatient (Part B) drugs that are furnished "incident to" a physician's service provided that the drugs are not usually self-administered by the patients who take them. Refer to the [Medicare Benefit Policy Manual, Chapter 15, §50 - Drugs and Biologicals](#). (Accessed July 8, 2024)

\*Preferred therapy criteria is not applicable for Medicare Advantage members.

## References

1. Bird S. Overview of the treatment of myasthenia gravis. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed on July 4, 2024.
2. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. *Lancet Neurol*. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7.
3. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. *Neurol Clin*. 2018;36(2):311-337.
4. Howard JF, Jr., Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicenter, randomized, placebo-controlled, phase 3 trial. *The Lancet Neurology*. 2021;20(7):526-536.
5. Mitsuma S, Van den Bergh P, Rajabally YA, et al. Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: a Japanese-European multicenter prospective study. *Clin Neurophysiol*. 2015;126:1805-1810.
6. Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. *Muscle Nerve*. 2022;65(6):630-639. doi:10.1002/mus.27476.
7. Muppidi S, Wolfe GI, Conaway M, Burns TM. MG-ADL: still a relevant outcome measure. *Muscle Nerve*. 2011;44(5):727-731.
8. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology*. 2021;96(3):114-122.
9. Rystiggo® [prescribing information]. Smyrna, GA: UCB, Inc.; June 2024.
10. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of

chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010 Mar;17(3):356-63. doi: 10.1111/j.1468-1331.2009.02930.x. Erratum in: Eur J Neurol. 2011 May;18(5):796. PMID: 20456730.

11. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021 Sep;26(3):242-268. doi: 10.1111/jns.12455. Epub 2021 Jul 30. Erratum in: J Peripher Nerv Syst. 2022 Mar;27(1):94. doi: 10.1111/jns.12479. Erratum in: Eur J Neurol. 2022 Apr;29(4):1288. doi: 10.1111/ene.15225. PMID: 34085743.

12. Vyvgart® [prescribing information]. Boston, MA: argenx US, Inc.; April 2025.

13. Vyvgart® Hytrulo [prescribing information]. Boston, MA: argenx US, Inc.; April 2025.

## Policy History/Revision Information

Date	Summary of Changes
10/01/2025	<p><b>Coverage Rationale</b></p> <ul style="list-style-type: none"> <li>Added language to indicate: <ul style="list-style-type: none"> <li>Imaavy™ (nipocalimab-aahu) has been added to the Review at Launch program and some members may not be eligible for coverage of this medication at this time; refer to the Medical Benefit Drug Policy titled <i>Review at Launch for New to Market Medications</i> for additional details</li> <li>Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) prefilled syringe for self-administered subcutaneous injection is obtained under the pharmacy benefit, <i>unless otherwise specified in the member's benefit plan documents; for members enrolled in UnitedHealthcare of California plans with a delegated provider group conducting the prior authorization review, the self-administered Vyvgart Hytrulo may be obtained under the medical benefit</i></li> </ul> </li> </ul> <p><b>Applicable Codes</b></p> <ul style="list-style-type: none"> <li>Updated list of applicable HCPCS codes to reflect quarterly edits; added C9305</li> </ul> <p><b>Supporting Information</b></p> <ul style="list-style-type: none"> <li>Archived previous policy version 2025D0111J</li> </ul>

## Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](#)).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.